AmerisourceBergen Inks 10 year Distribution Deal with Drugsellers
The long-term distribution deal with Walgreens and Alliance Boots is expected to add an incremental $28 billion in revenues, according to AmerisourceBergen.
Archives for March 19, 2013
AstraZeneca R&D rejig will impact commercial and manufacturing ops
The ‘R&D’ reorganisation announced by AstraZeneca yesterday will impact manufacturing and commercial operations as well drug development activities.
Sanofi Manufacturing ‘Delays’ Cause Shortage of TB Drug
Manufacturing “delays” at an unidentified Sanofi-Aventis plant have caused a new shortage of a tuberculosis (TB) drug, according to the US FDA.
AB Technology Buys Angel's Edinburgh Assets
As the dissolution of Angel continues, its core manufacturing facility has been bought by AB Technology ensuring long term operations and rescuing 23 jobs.
FDA’s Tablet ‘Scoring’ Guidance Aims to Bridge Generic, Brand Divide
Marketed drugs will not need to be tested under final guidelines on 'tablet scoring' for branded and generic medicines issued by the US Food and Drug Administration (FDA) this week.
CRO Group Says More Reductions in UK Early Phase Research Likely
The UK’s CCRA (Clinical Contract Research Association) says the number of Phase 1 clinical trials in the UK has “decreased substantially” since 2003 and is likely to be further diminished in the next few years.
Preclinical Data Fraud is 'Rare' says UK MHRA and Rule Rejig Not Needed
Fraudulent manipulation of preclinical trial data is rare and the regulations that cover this type of research do not need to be revised according to the UK MHRA.
$2.25m Settlement as Teva Pushed to Address API Site's Green issues
The US Environmental Protection Agency (EPA) says Teva still needs to address environmental issues at Missouri API plant landed with a $2.3m civil penalty.